Biotechnology company Moderna, Inc. (NASDAQ: MRNA) reported a sharp decline in revenues and earnings for the fourth quarter of 2023. Net income
Moderna Inc
-(MRNA)
XNAS:MRNA
Moderna, Inc Q2 2023 Earnings Conference Call Insights
Key highlights from Moderna, Inc (MRNA) Q2 2023 Earnings Concall Management Update: [00:16:30] MRNA’s COVID sales expectations for 2023 are in the
Infographic: Moderna (MRNA) Q2 2023 Earnings Results
Moderna, Inc. (NASDAQ: MRNA) reported second quarter 2023 earnings results today. Total revenue dropped to $344 million from $4.7 billion in the
Key highlights from Moderna’s (MRNA) Q1 2023 earnings results
Moderna, Inc. (NASDAQ: MRNA) reported first quarter 2023 earnings results today. Total revenue was $1.9 billion, compared to $6.1 billion in the
Moderna Inc (MRNA) Q4 2022 Earnings Call Transcript
Moderna Inc (NASDAQ:MRNA) Q4 2022 Earnings Call dated Feb. 23, 2023. Corporate Participants: Lavina Talukdar -- Head of Investor Relations Stephane Bancel -- Chief Executive Officer
Moderna (MRNA) Earnings: 4Q22 Key Numbers
Moderna Inc. (NASDAQ: MRNA) reported total revenue of $5.1 billion for the fourth quarter of 2022, down 29% year-over-year due to a
Moderna Inc (MRNA) Q3 2022 Earnings Call Transcript
Moderna Inc (NASDAQ:MRNA) Q3 2022 Earnings Call dated Nov. 03, 2022. Corporate Participants: Lavina Talukdar -- Head of Investor Relations Stephane Bancel -- Chief Executive Officer
Moderna, Inc. (MRNA) Q1 2022 Earnings Call Transcript
Moderna, Inc. (NASDAQ: MRNA) Q1 2022 earnings call dated Aug. 03, 2022 Corporate Participants: Lavina Talukdar -- Senior Vice President and Head of Investor
Moderna Inc. (MRNA) Q1 2022 Earnings Call Transcript
Moderna Inc. (NASDAQ: MRNA) Q1 2022 earnings call dated May. 04, 2022 Corporate Participants: Lavina Talukdar -- Senior Vice President and Head of Investor
Moderna, Inc. (MRNA) Q4 2021 Earnings Call Transcript
Moderna, Inc. (NASDAQ: MRNA) Q4 2021 earnings call dated Feb. 24, 2022 Corporate Participants: Lavina Talukdar -- Senior Vice President & Head of Investor Relations
Moderna (MRNA): Here are a few points to note while considering this stock
Shares of Moderna Inc. (NASDAQ: MRNA) were up 6% on Monday. The stock has gained 291% since the beginning of the year
Moderna, Inc. (MRNA) Q2 2021 Earnings Call Transcript
Moderna, Inc. (NASDAQ: MRNA) Q2 2021 earnings call dated Aug. 05, 2021 Corporate Participants: Lavina Talukdar -- Senior Vice President & Head of Investor
Earnings calendar for the week of August 2
Labor market conditions improved once again and jobless claims dropped to about 400,000 after rising last week, as economic activity picked up.
Moderna, Inc. (MRNA) Q1 2021 Earnings Call
Moderna, Inc. (NASDAQ: MRNA) Q1 2021 earnings call dated May. 06, 2021 Corporate Participants: Lavina Talukdar — Senior Vice President and Head of Investor Relations
Moderna, Inc. (MRNA) Q1 2021 Earnings Call Transcript
Moderna, Inc. (NASDAQ: MRNA) Q1 2021 earnings call dated May. 06, 2021 Corporate Participants: Lavina Talukdar -- Senior Vice President and Head of Investor
Moderna (MRNA): COVID-19 vaccine helps company deliver first ever profitable quarter
Shares of Moderna Inc. (NASDAQ: MRNA) were down 3% in morning hours on Thursday despite the company reporting the first profitable quarter
Earnings calendar for the week of May 3
Leading stock indexes retreated after gaining mid-week when Wall Street biggies like Apple and Amazon reported impressive quarterly numbers. The Dow Jones
What’s happening on the COVID-19 front? Here are a few updates.
Right about this time last year, the COVID-19 pandemic took over the world with full force as several countries went into complete
Moderna (MRNA) to increase vaccine supply capacity and accelerate pipeline investments
Shares of Moderna Inc. (NASDAQ: MRNA) were up 6% in morning trade on Thursday after the company reported its fourth quarter and
Where do these companies stand in the COVID-19 vaccine race?
After the struggle with the COVID-19 pandemic and its impacts clouding most of 2020, the rollout of vaccines against COVID-19 is the
Moderna (MRNA): Development programs, additional approvals provide optimism
Moderna Inc. (NASDAQ: MRNA) seems to be on a roll right now. The stock has skyrocketed over 500% in the past one